ZA917170B - Novel antibodies for treatment and prevention of infection in animals and man - Google Patents

Novel antibodies for treatment and prevention of infection in animals and man

Info

Publication number
ZA917170B
ZA917170B ZA917170A ZA917170A ZA917170B ZA 917170 B ZA917170 B ZA 917170B ZA 917170 A ZA917170 A ZA 917170A ZA 917170 A ZA917170 A ZA 917170A ZA 917170 B ZA917170 B ZA 917170B
Authority
ZA
South Africa
Prior art keywords
infection
man
animals
prevention
treatment
Prior art date
Application number
ZA917170A
Inventor
William J Harris
J Harris William
Philip R Tempest
R Tempest Philip
Geraldine Taylor
Taylor Geraldine
Original Assignee
Scotgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotgen Ltd filed Critical Scotgen Ltd
Publication of ZA917170B publication Critical patent/ZA917170B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA917170A 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection in animals and man ZA917170B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man

Publications (1)

Publication Number Publication Date
ZA917170B true ZA917170B (en) 1992-07-29

Family

ID=10682003

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917170A ZA917170B (en) 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection in animals and man

Country Status (12)

Country Link
EP (1) EP0548190A1 (en)
JP (1) JPH06501152A (en)
KR (1) KR930702519A (en)
AU (1) AU654827B2 (en)
CA (1) CA2091335A1 (en)
GB (1) GB9019812D0 (en)
IE (1) IE913177A1 (en)
MX (1) MX9101046A (en)
NZ (1) NZ239728A (en)
PT (1) PT98944B (en)
WO (1) WO1992004381A1 (en)
ZA (1) ZA917170B (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP2631767B2 (en) * 1990-07-19 1997-07-16 アメリカ合衆国 Aerosol for prevention or treatment of viral respiratory disease
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
DE69233750D1 (en) 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
DK0671927T3 (en) * 1992-09-16 2003-04-22 Us Gov Health & Human Serv Neutralizing human monoclonal antibodies against respiratory syncytial virus
DE69419721T2 (en) 1993-01-12 2000-04-27 Biogen Inc RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES
CA2167835A1 (en) * 1993-07-30 1995-02-09 Richard A. Weltzin Monoclonal iga antibody against respiratory syncytial virus
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
WO1997010846A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
EP1378525A3 (en) 1996-06-07 2004-01-14 Neorx Corporation Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
WO1998032855A1 (en) 1997-01-27 1998-07-30 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
ES2374621T3 (en) 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. MEANS TO ASSESS THE RISK PROFILE OF AN INDIVIDUAL OF SUFFERING AN ATEROSCLEROTIC DISEASE.
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
WO2000040614A2 (en) 1998-12-30 2000-07-13 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
AU5632500A (en) 1999-06-30 2001-01-31 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
DK1207905T3 (en) 1999-09-03 2011-01-03 Brigham & Womens Hospital Methods and compositions for the treatment of inflammatory disease using cadherin-II modulating agents
JP2003512057A (en) 1999-10-19 2003-04-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ MAGE-A12 antigen peptide and use thereof
SI20976A (en) * 1999-12-23 2003-02-28 Icn Pharmaceuticals, Inc. Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
DE10211088A1 (en) 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
HUE027779T2 (en) 2002-05-09 2016-11-28 Brigham & Womens Hospital Inc 1L1RL-1 as a cardiovascular disease marker
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
WO2004072275A2 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
HUE027546T2 (en) 2003-08-29 2016-10-28 Brigham & Womens Hospital Inc Hydantoin derivatives as inhibitors of cellular necrosis
DE10341812A1 (en) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
DE10344799A1 (en) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004023187A1 (en) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
DE102005059242A1 (en) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molecular markers for tumor diagnosis and therapy
JP4977691B2 (en) 2006-04-13 2012-07-18 中外製薬株式会社 Taurine transporter gene
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
EP2463303B1 (en) 2007-02-23 2014-04-30 The United States of America as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that neutralize anthrax toxins
WO2008114673A1 (en) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
CN101809161B (en) 2007-08-07 2014-03-12 中外制药株式会社 Method of producing heterogeneous protein
JP5337043B2 (en) 2007-10-15 2013-11-06 中外製薬株式会社 Method for producing cells producing high production of heterologous protein
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN101821403B (en) * 2007-10-24 2014-01-01 中外制药株式会社 Cell for use in the production of exogenous protein, and production process using the cell
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
AU2009274129B2 (en) * 2008-07-21 2016-02-25 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
KR102340685B1 (en) 2009-02-20 2021-12-17 가니메드 파마슈티칼스 게엠베하 Methods and compositions for diagnosis and treatment of cancer
JP5715050B2 (en) 2009-04-22 2015-05-07 中外製薬株式会社 Method for producing cells producing high production of heterologous protein
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
BR112012011143B1 (en) 2009-11-11 2020-05-19 Ganymed Pharmaceuticals Ag "antibodies specific for claudin 6 (cldn6)".
LT2558499T (en) 2010-04-16 2017-07-25 Biogen Ma Inc. Anti-vla-4 antibodies
WO2011133894A2 (en) 2010-04-23 2011-10-27 Purdue Research Foundation Protein drug formulations and packages
KR20190000385A (en) 2010-05-04 2019-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. Detection and treatment of fibrosis
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
MX341147B (en) 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6.
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
BR112016017046A2 (en) 2014-01-24 2017-10-03 Henry M Jackson Found Advancement Military Medicine Inc ANTIBODIES AGAINST GLYCOPROTEIN F FROM HENDRA AND NIPAH VIRUSES
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
WO2017147258A1 (en) 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Emapii neutralizing antibody limits influenza a virus (iav)-induced lung injury
WO2017213695A1 (en) 2016-06-07 2017-12-14 The Brigham And Women's Hospital, Inc. Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb

Also Published As

Publication number Publication date
KR930702519A (en) 1993-09-09
EP0548190A1 (en) 1993-06-30
CA2091335A1 (en) 1992-03-12
WO1992004381A1 (en) 1992-03-19
PT98944A (en) 1992-08-31
GB9019812D0 (en) 1990-10-24
JPH06501152A (en) 1994-02-10
NZ239728A (en) 1995-07-26
AU654827B2 (en) 1994-11-24
AU8505891A (en) 1992-03-30
IE913177A1 (en) 1992-03-11
MX9101046A (en) 1992-05-04
PT98944B (en) 1999-02-26

Similar Documents

Publication Publication Date Title
ZA917170B (en) Novel antibodies for treatment and prevention of infection in animals and man
GB9207479D0 (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
SG49658A1 (en) Treatment of condition and disease
GB9203206D0 (en) Treatment of particulate material
GB9014307D0 (en) Method of treatment and compositions therefor
ZA914435B (en) Treatment of disease
FR2663230B1 (en) HYGIENE AND TREATMENT DEVICE.
GB2263905B (en) Treatment of waste animal materials
EP0540575A4 (en) Human meg-csf protein and methods
IL101749A0 (en) Treatment of mastitis
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
KR960006863B1 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
EG20171A (en) Treatment of conditions and disease
ZA914464B (en) Method and compositions for treating hiv-type 1 infection
GB9216360D0 (en) Treatment of blood
GB2245475B (en) Improvements in the treatment of animal feeds
RU1833740C (en) Way of treatment and prophylaxis of allergic diseases of reagent type
GB9021960D0 (en) Treatment of flax
RU1785692C (en) Preparation for treatment and prophylaxis piglets colibacteriosis
RU1833739C (en) Way of treatment hyperekaliemia
ZA903993B (en) Treatment of animals
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
GB9013938D0 (en) Vaccine and treatment for the prevention of type i or juvenile diabetes
NZ231322A (en) Treatment of viral and/or bacterial infections
NZ233973A (en) Treatment of viral and/or bacterial infections